Clinical Trials 101 | Page 3 | Alzheimer's Prevention Registry

You are here

Clinical Trials 101

Alzheimer’s research reset

After some costly and disappointing drug trial failures, the field welcomes a funding surge, tools for tracking disease, and interdisciplinary collaborations to tackle one of science’s most stubborn puzzles.

A road map for including Latinos and African Americans in Alzheimer’s research

Alzheimer’s disease is the only leading cause of death in the U.S. that is still on the rise and that does not have a current effective treatment or cure. The limited inclusion of Latinos and African Americans in research will only worsen the outlook, though the success of efforts bubbling up across the country could help us keep up with the disease.

China approves Alzheimer's drug, inviting fresh debate in field with few successes

In a decision likely to stir scientific debate across the world, China's health regulator conditionally approved a new Alzheimer's drug for patients with mild-to-moderate forms of the neurodegenerative disease. 

Why Didn’t She Get Alzheimer’s? The Answer Could Hold a Key to Fighting the Disease

Researchers have found a woman with a rare genetic mutation that has protected her from dementia even though her brain has developed major neurological features of the disease.

A Genetic Test That Reveals Alzheimer's Risk Can Be Cathartic Or Distressing

In a waiting room at the Banner Alzheimer's Institute in Phoenix, a 74-year-old woman named Rubie is about to find out whether she has a gene that puts her at risk for Alzheimer's.

More studies seek people with mild cognitive impairment

In order to get ahead of Alzheimer’s disease earlier, more and more research studies are seeking people without changes to their memory and thinking along with those with a condition known as mild cognitive impairment (MCI). The question is, how do you know if you have it?

Alzheimer’s Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer’s Disease

The Alzheimer’s Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) and the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, which are currently being evaluated as treatments for early Alzheimer’s disease (AD), have been selected by the ACTC as treatments to be evaluated in upcoming clinical studies targeting primary prevention (A3 Study) and secondary prevention (A45 Study) of AD. These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai.

Biogen Ends Late-Stage Alzheimer’s Trials, Crushing Hopes and Calling Amyloid Into Question

Clinical trial participants, researchers and investors were reeling on Thursday after Biogen and Eisai, its Japanese pharmaceutical partner, announced that they would be halting two Stage 3 clinical trials that had previously reported positive results. Biogen said the drug, aducanumab, was unlikely to help patients.

An Alzheimer’s Drug Trial Gave Me Hope, and Then It Ended

I was a small piece in the search to find a cure. Now I feel as if I’m getting erased, and medical science doesn’t have any answers.